Miao Jiang, Gao LiXuan, Liu Xi, Cai Wenpin, Chen Lei, Chen Mojinzi, Sun Yun
Department of Pharmacy, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, China.
Department of Rehabilitation Medicine, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, China.
Front Med (Lausanne). 2024 Oct 3;11:1455964. doi: 10.3389/fmed.2024.1455964. eCollection 2024.
The incidence of Polycystic Ovary Syndrome (PCOS) is increasing annually. This study aims to investigate the therapeutic mechanisms of Yikang Decoction (YKD) in the treatment of PCOS through the integration of GEO datasets, network pharmacology, and dynamic simulation.
Active ingredients of YKD and their targets were collected from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) platform. Disease-relevant targets for PCOS were retrieved from several databases, including GeneCards, OMIM, PharmGKB, DrugBank, and GEO. The underlying pathways associated with the overlapping targets between YKD and PCOS were identified using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. The mechanisms of interaction between the core targets and components were further explored through molecular docking and molecular dynamics simulations (MD).
139 potential active components and 315 targets of YKD were identified. A topological analysis of the PPI network revealed 10 core targets. These targets primarily participated in the regulation of biological processes, including cell metabolism, apoptosis, and cell proliferation. The pathways associated with treating PCOS encompassed PI3K-Akt signaling pathway, Lipid and atherosclerosis, MAPK signaling pathways, and Endocrine resistance signaling pathways. Moreover, molecular docking and MD have been shown to reveal a good binding capacity between active compounds and screening targets.
This study systematically investigates the multi-target mechanisms of YKD in the treatment of PCOS, with preliminary verification provided through molecular docking and MD. The findings offer compelling evidence supporting the efficacy of YKD in treating PCOS.
多囊卵巢综合征(PCOS)的发病率逐年上升。本研究旨在通过整合基因表达综合数据库(GEO)数据集、网络药理学和动态模拟,探讨益康汤(YKD)治疗PCOS的作用机制。
从中药系统药理学(TCMSP)平台收集YKD的活性成分及其靶点。从多个数据库检索PCOS的疾病相关靶点,包括基因卡片(GeneCards)、在线人类孟德尔遗传数据库(OMIM)、药物基因组学知识库(PharmGKB)、药物银行(DrugBank)和GEO。使用基因本体论(GO)和京都基因与基因组百科全书(KEGG)富集分析确定YKD和PCOS之间重叠靶点相关的潜在通路。通过分子对接和分子动力学模拟(MD)进一步探索核心靶点与成分之间的相互作用机制。
确定了YKD的139种潜在活性成分和315个靶点。蛋白质-蛋白质相互作用(PPI)网络的拓扑分析显示有10个核心靶点。这些靶点主要参与生物过程的调节,包括细胞代谢、凋亡和细胞增殖。与治疗PCOS相关的通路包括磷脂酰肌醇-3激酶-蛋白激酶B(PI3K-Akt)信号通路、脂质与动脉粥样硬化、丝裂原活化蛋白激酶(MAPK)信号通路和内分泌抵抗信号通路。此外,分子对接和MD已显示活性化合物与筛选靶点之间具有良好的结合能力。
本研究系统地研究了YKD治疗PCOS的多靶点机制,并通过分子对接和MD进行了初步验证。研究结果为YKD治疗PCOS的疗效提供了有力证据。